NEWRON PHARMACEUT. EO-20 Net Assets
NEWRON PHARMACEUT. EO-20 net assets. Based on the latest financial reports, NEWRON PHARMACEUT. EO-20 (NP5) has net assets worth €-11.13 Million EUR (≈ $-13.02 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€40.05 Million ≈ $46.83 Million USD) and total liabilities (€51.19 Million ≈ $59.85 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore NP5 net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €-11.13 Million |
| % of Total Assets | -27.8% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 156.08 |
Net Assets of NEWRON PHARMACEUT. EO-20 (2021–2025)
Net assets of NEWRON PHARMACEUT. EO-20 from 2021 to 2025. This chart illustrates how NEWRON PHARMACEUT. EO-20's net assets have evolved over time, based on quarterly financial data. See NP5 net asset quality index to measure how much of total assets are equity-financed.
Annual Net Assets for NEWRON PHARMACEUT. EO-20 (2021–2025)
The table below shows the annual net assets of NEWRON PHARMACEUT. EO-20 from 2021 to 2025. For live market cap and overall valuation, see how much is NEWRON PHARMACEUT. EO-20 worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €-11.13 Million ≈ $-13.02 Million |
-863.72% |
| 2024-12-31 | €1.46 Million ≈ $1.70 Million |
+104.87% |
| 2023-12-31 | €-29.91 Million ≈ $-34.97 Million |
-113.17% |
| 2022-12-31 | €-14.03 Million ≈ $-16.40 Million |
-551.56% |
| 2021-12-31 | €3.11 Million ≈ $3.63 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to NEWRON PHARMACEUT. EO-20's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 185100000.0% over the analyzed period, indicating profitable operations and earnings retention.
NEWRON PHARMACEUT. EO-20 Net Assets Breakdown (December 2025)
NEWRON PHARMACEUT. EO-20 net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €7.13 Million | % |
| Total Equity | €-11.13 Million | 100.00% |
NEWRON PHARMACEUT. EO-20 Competitors by Market Cap
The table below lists competitors of NEWRON PHARMACEUT. EO-20 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Odfjell B
OL:ODFB
|
$228.69 Million |
|
Dong-A St
KO:170900
|
$228.74 Million |
|
Kaltura Inc
NASDAQ:KLTR
|
$228.83 Million |
|
Baoding Dongli Machinery Co.Ltd.
SHE:301298
|
$228.99 Million |
|
Aurelius Technologies Bhd
KLSE:5302
|
$228.59 Million |
|
Cint Group AB
ST:CINT
|
$228.55 Million |
|
Gunung Raja Paksi
JK:GGRP
|
$228.52 Million |
|
Penns Woods Bancorp Inc
NASDAQ:PWOD
|
$228.43 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in NEWRON PHARMACEUT. EO-20's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,458,000 to -11,135,000, a change of -12,593,000 (-863.7%).
- Net loss of 13,239,000 reduced equity.
- New share issuances of 350,000 increased equity.
- Other factors increased equity by 296,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-13.24 Million | -118.9% |
| Share Issuances | €350.00K | +3.14% |
| Other Changes | €296.00K | +2.66% |
| Total Change | €- | -863.72% |
Book Value vs Market Value Analysis
This analysis compares NEWRON PHARMACEUT. EO-20's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €0.17 | €9.40 | x |
| 2022-12-31 | €-0.79 | €9.40 | x |
| 2023-12-31 | €-1.68 | €9.40 | x |
| 2024-12-31 | €0.07 | €9.40 | x |
| 2025-12-31 | €-0.56 | €9.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently NEWRON PHARMACEUT. EO-20 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -69.22%
- • Asset Turnover: 0.48x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (121.41%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -479.59% | -258.61% | 0.11x | 16.25x | €-15.21 Million |
| 2022 | 0.00% | -287.05% | 0.16x | 0.00x | €-16.09 Million |
| 2023 | 0.00% | -179.13% | 0.35x | 0.00x | €-13.23 Million |
| 2024 | 1086.63% | 30.83% | 0.80x | 43.83x | €15.70 Million |
| 2025 | 0.00% | -69.22% | 0.48x | 0.00x | €-12.13 Million |
Industry Comparison
This section compares NEWRON PHARMACEUT. EO-20's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $82,275,373
- Average return on equity (ROE) among peers: -15.87%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| NEWRON PHARMACEUT. EO-20 (NP5) | €-11.13 Million | -479.59% | N/A | $228.65 Million |
| TME PHARM.CONF.IPO EO 1- (0N6A) | $-294.00K | 0.00% | 0.00x | $10.44 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $88.56 Million | -31.35% | 0.90x | $141.29 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $19.57 Million | -78.67% | 0.35x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $-223.84 Million | 0.00% | 0.00x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $230.94 Million | -20.03% | 0.13x | $125.74 Million |
| PreveCeutical Medical Inc (18H) | $-3.60 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $538.39 Million | -12.38% | 0.07x | $41.67 Billion |
| GH RESEARCH PLC DL-025 (1KA) | $218.97 Million | -16.25% | 0.03x | $1.22 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $-45.09 Million | 0.00% | 0.00x | $699.56 Million |
| BIOCURE TECHNOLOGY INC. (1WH) | $-852.32K | 0.00% | 0.00x | $960.84K |
About NEWRON PHARMACEUT. EO-20
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company's… Read more